Michael Ehlers and Romesh Subramanian launch biotech with $50M, sea squirt-inspired RNA-editing tech
So, sea squirts.
More elegantly known as ascidians, these early vertebrates metamorphose from tadpoles into their tube-like, immobile adult forms. To do that, ascidians edit their RNA — through a technique that former Biogen R&D chief and current ATP CSO Michael Ehlers has co-opted for his latest biotech, Ascidian Therapeutics.
Ascidian (the biotech one) started right at the cusp of the pandemic, and is now launching out of stealth with $50 million. A month ago, Romesh Subramanian, founder and former CEO of muscle disease-focused Dyne Therapeutics, came on as CEO, taking the reins from Ehlers, who will move to board chair.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.